To Get Full Access :

Leqselvi

Leqselvi is an oral tablet prescribed for adults with severe alopecia areata, a condition that causes widespread hair loss. It works by blocking specific Janus kinase enzymes involved in the autoimmune process, leading to significant hair regrowth over 30% of patients saw at least 80% scalp coverage in clinical trials

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Deuruxolitinib
  • Innovator :

    SUN PHARMACEUTICAL INDUSTRIES INC
  • Approval Date :

    25-Jul-24
  • NCE-1 Date :

    25-Jul-28
  • NCE Date :

    25-Jul-29
  • Dosage Form :

    Oral Tablets
  • Strength :

    8 mg
  • Therapeutic Category :

    Immunomodulators
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2026 :

    51
  • 2027 :

    91
  • 2028 :

    124
  • 2029 :

    159
  • 2030 :

    194
  • 2031 :

    229
  • 2032 :

    264
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?